Innovent Biologics
China's leading biotech company pioneering affordable cancer immunotherapy
Company Overview
Innovent Biologics is one of China's most innovative biopharmaceutical companies, focused on developing affordable cancer immunotherapies and biologics. The company's PD-1 inhibitor Tyvyt was the first domestically developed PD-1 therapy approved in China. Innovent has extensive partnerships with Eli Lilly and other global pharma companies, and is expanding its pipeline into autoimmune diseases and metabolic disorders.
この企業が重要な理由
Innovent represents China's ambition to become a global leader in biologic drug innovation, not just manufacturing, with a pipeline that increasingly targets global markets.
主要注力分野
同業他社
Signal Timeline
0 件No signals tracked yet for this company.
Signals will appear here as official announcements are indexed.
この企業の公式チャネルを監視中です。シグナルが発見され次第表示されます。
この企業の新しいシグナルが公開されたら通知を受け取る。